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Background.  Low muscle mass and weakness are common and potentially disabling in older adults, but in order to 
become recognized as a clinical condition, criteria for diagnosis should be based on clinically relevant thresholds and 
independently validated. The Foundation for the National Institutes of Health Biomarkers Consortium Sarcopenia Project 
used an evidence-based approach to develop these criteria. Initial findings were presented at a conference in May 2012, 
which generated recommendations that guided additional analyses to determine final recommended criteria. Details of 
the Project and its findings are presented in four accompanying manuscripts.
Methods.  The Foundation for the National Institutes of Health Sarcopenia Project used data from nine sources of com-
munity-dwelling older persons: Age, Gene/Environment Susceptibility-Reykjavik Study, Boston Puerto Rican Health 
Study, a series of six clinical trials, Framingham Heart Study, Health, Aging, and Body Composition, Invecchiare in 
Chianti, Osteoporotic Fractures in Men Study, Rancho Bernardo Study, and Study of Osteoporotic Fractures. Feedback 
from conference attendees was obtained via surveys and breakout groups.
Results. The pooled sample included 26,625 participants (57% women, mean age in men 75.2 [±6.1 SD] and in 
women 78.6 [±5.9] years). Conference attendees emphasized the importance of evaluating the influence of body mass on 
cutpoints. Based on the analyses presented in this series, the final recommended cutpoints for weakness are grip strength 
<26  kg for men and <16  kg for women, and for low lean mass, appendicular lean mass adjusted for body mass index 
<0.789 for men and <0.512 for women.
Conclusions.  These evidence-based cutpoints, based on a large and diverse population, may help identify participants 
for clinical trials and should be evaluated among populations with high rates of functional limitations.
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T
HE term “sarcopenia” originally referred solely to the 
loss of muscle mass with age, and as such, is an almost 
universal phenomenon (1,2). Although the term “sarcope-
nia” has become widely used in the literature, definitions 
vary, due to greater insights into the relationships between 
muscle mass, muscle quality, muscle strength, and func-
tion. Recent literature suggests that the role of muscle mass 
in function and health appears to be indirect. Although not 548  StuDENSkI Et AL.
entirely consistent, the weight of evidence in community-
dwelling older adults suggests that (i) low muscle mass 
is associated with weakness (3), (ii) weakness (now often 
referred to as “dynapenia”) (4) is strongly associated with 
function and disability (5,6), but (iii) low muscle mass 
alone is weakly or not associated with function and disabil-
ity (7,8). Because of these findings, current “sarcopenia” 
definitions incorporate not only muscle mass but also ele-
ments such as strength and function.
It is clear that we can no longer assume that there is a 
direct and strong causal pathway from mass to strength to 
function. On the other hand, there does appear to be a pop-
ulation of adults who have functional limitations because 
they are weak, and they are weak in part because they 
have low muscle mass. One conceptual and analytic strat-
egy to identify this population is to take the approach of 
a clinician making a “differential diagnosis.” The clinician 
understands that there are many causes of reduced physi-
cal function, one of which is weakness. Similarly, low lean 
mass, an indicator of muscle mass based on imaging, may 
be considered one of many contributing factors in the devel-
opment of weakness (Figure 1). Thus, it would be reason-
able to identify individuals with low lean mass contributing 
to weakness because these individuals may benefit from 
interventions that are specifically designed to address mus-
cle mass. Persons without low muscle mass as a cause of 
their weakness may require different interventions.
The original criteria for low lean mass, which have 
largely been carried forward into all proposed definitions, 
were based on distributional characteristics in modest sized 
populations, rather than on potential clinical relevance in 
large, diverse populations. Thus, a key gap in knowledge 
remains: What degree of low lean mass is clinically rele-
vant, when it is empirically grounded to its relationship to 
strength and function?
To determine critical thresholds for low lean mass that 
are based on its relationship to strength and function, the 
Foundation for the National Institutes of Health (FNIH) 
Biomarkers Consortium, a public–private partnership com-
posed of representatives from the National Institute of Aging, 
National Institute of Arthritis and Musculoskeletal and Skin 
Diseases, Center for Drug Evaluation and Research/Food 
and Drug Administration, several prominent academic 
institutions, and six pharmaceutical companies, approved 
support for an initiative entitled, “The FNIH Sarcopenia 
Project.” The project’s goal was to use multiple existing data 
sources to identify criteria for clinically relevant weakness 
and low lean mass. In 2009, the FNIH released a Request for 
Proposals (RFP) to participate in a Consortium that would 
address the following major goals: using mobility impair-
ment as the clinically relevant state of function (i) define a 
clinically relevant degree of muscle weakness; (ii) define a 
clinically relevant degree of low lean mass associated with 
muscle weakness; (iii) determine, among those without cur-
rent mobility limitations, whether these weakness and low 
lean mass criteria predict future mobility limitations; and 
(iv) compare these criteria for weakness and low lean mass 
to other proposed criteria. The Request for Proposals eligi-
bility requirements included: (i) existing data set; (ii) lon-
gitudinal cohort or clinical trial study design with data at a 
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minimum of two time points; (iii) inclusion of older adults; 
(iv) available measures of body composition, strength, and 
physical performance; and (v) willingness to share data and 
analysis plans with other investigators. Investigators from 
nine sets of studies participated in an initial planning meet-
ing in March 2010, where they agreed to: (i) use mobility 
impairment, assessed by physical performance measures, 
as the criterion for a clinical state of physical function that 
is relevant to muscle; (ii) define mobility impairment from 
clinically relevant thresholds of physical performance tests 
such as slow walking or inability to rise from a chair; and 
(iii) apply clinically relevant analytic strategies, includ-
ing classification and regression tree analysis and receiver 
operating characteristic curves. At a later time, a decision 
was made to increase statistical power by pooling the origi-
nal data rather than meta-analyze individual study results. 
Finally, due to current confusion related to the meaning of 
the word “sarcopenia,” we decided to avoid using the term 
itself and consistently employ only the terms “low lean 
mass” and “weakness.”
A key step in the process of developing these criteria was 
to obtain feedback on preliminary findings of the FNIH 
Sarcopenia Project from representatives from academia, 
professional organizations, government, and the private 
sector who have an interest in the area of aging and muscle. 
Therefore, a conference was held in May 2012 to elicit pri-
orities and perspectives, provide feedback on the progress 
of the FNIH Sarcopenia Project team, and make recom-
mendations for next steps. This manuscript summarizes the 
findings from the Conference, the results of final analyses, 
and identifies key next steps.
The purpose of this first manuscript of a set of five, 
derived from the work of the FNIH Sarcopenia Project, 
is twofold. First, to present the characteristics of the par-
ticipating studies, including study design, sample size, 
demographics, baseline status of key indicators of physical 
function, strength, and body composition, and additional 
indicators of health and disease. Second, we summarize 
the recommendations from the Conference that led to the 
final set of analyses presented in this series of articles. 
The second manuscript in the series focuses on develop-
ing clinically relevant criteria for weakness based on grip 
strength (9); the third on criteria for low muscle mass (10); 
the fourth on longitudinal predictions based on the weak-
ness and muscle mass criteria (11); and the fifth presents 
comparisons between the FNIH Project findings and previ-
ously published operational definitions for sarcopenia (12). 
We hope that these findings can support further develop-
ment of a robust and well-validated clinical definition of 
“sarcopenia” that would aid in critical appraisal of existing 
literature, help guide eligibility and measurement in future 
studies, support the assessment of interventions, either as 
a target group for treatment or as part of an endpoint, and 
eventually be used to help develop diagnostic criteria and 
indications for clinical treatments in practice.
Methods
overview
This Methods section has two goals; our first goal is to 
present the study design, population sample, and key meas-
ures from the nine participating studies. Because the goals 
of the cross-sectional analyses required that there be suf-
ficient cases of mobility impairment, for some cohorts, we 
selected a wave and study time point that optimized the 
prevalence of mobility impairment and sample size. Our 
second goal is to summarize the methods we used to obtain 
feedback during the conference in May 2012.
For the purpose of defining our primary outcome, mobil-
ity impairment, we selected a usual gait speed ≤ 0.8 m/s 
because it predicts reduced overall survival (13), disabil-
ity (14), and has been recommended by other experts (15). 
In addition, we planned sensitivity analyses using other 
cutpoints for gait speed (0.6 and 1.0 m/s). We considered 
inability to rise from a chair as an alternate definition of 
mobility impairment because it is potentially more strongly 
related to muscle strength compared with gait speed and 
has also been recommended by expert panels (15). Grip 
strength was used as the primary measure of muscle 
strength because it was widely available in all nine studies, 
whereas lower extremity strength measures varied greatly 
and were available in only a few studies. Written informed 
consent had been obtained from each participant and each 
study was approved by the institutional review boards at 
each institution.
Collaborating Studies
Age, Gene/Environment Susceptibility-Reykjavik Study.— 
In 2002–2006, adults aged ≥65 years who originally partic-
ipated in the Reykjavik Study (1967–1997) were recruited 
to participate in an interdisciplinary genetic epidemiology 
study of the musculoskeletal, body composition, neuro-
cognitive, and vascular systems including assessment of 
function by both self-report and performance (16). The 
objective of the study was to identify shared biological 
pathways for disease and to test gene–environment inter-
actions. Participants were seen approximately 5 years 
later in 2007–2011 for follow-up. Data on body composi-
tion and/or physical performance from the baseline visit 
were available in 5,764 participants (2,438 men and 3,326 
women).
Boston Puerto Rican health Study.—In 2004–2007, 
1,505 men and women aged 45–75  years and living in 
Massachusetts were recruited to examine the relationships 
between life stressors and physical and psychosocial health 
(17). Data on body composition and/or physical perfor-
mance from the baseline visit were available in 249 partici-
pants (63 men and 186 women) aged ≥65 years.550  StuDENSkI Et AL.
Clinical trials.—This study included data from six 
different clinical trials conducted at the University of 
Connecticut. Recruitment and enrollment criteria varied. 
Participants were randomized to active or placebo group 
with various interventions including testosterone, estradiol, 
omega-3, exercise, and dehydroepiandrosterone with Yoga 
or aerobics (18–23). The study duration ranged between 6 
and 36 months. Data on body composition and/or physical 
performance from the randomization visits were available 
in 651 participants (184 men and 467 women).
Framingham heart Study.—In 1948, the Framingham 
Heart Study (FHS) Original cohort recruited two thirds of 
the population sample from Framingham, Massachusetts, 
to evaluate risk factors of heart disease (24). In 1971, adult 
children of the FHS Original cohort were recruited to the 
FHS Offspring cohort to understand familial risk factors of 
heart disease (25). This study includes data from the FHS 
Original cohort and FHS Offspring cohort. Participants 
were seen at 2- to 4-year intervals. Data on body composi-
tion and/or physical performance were available in 469 par-
ticipants (151 men and 318 women) from the FHS Original 
cohort (exam cycle 22, 1992–1993) and in 1,175 partici-
pants (558 men and 617 women) from the FHS Offspring 
cohort (exam cycle 6 and 7, 1996–2001).
health, Aging, and Body Composition Study.—In 1997–
1998, 3,075 men and women aged 70–79 years who reported 
no difficulty walking 0.25 mile and climbing a flight of 
stairs and were free of disability in activities of daily living 
were recruited at two clinical centers (Memphis, Tennessee 
and Pittsburgh, Pennsylvania) to evaluate whether change 
in body composition is a common pathway contribut-
ing to disability (26). The study oversampled for African 
Americans and was 42% black and 48% men. Participants 
were seen yearly for the first 6 years and then every other 
year until the 10th year with continuing follow-up by exam-
ination and phone contact. Because the FNIH Sarcopenia 
Project focused on more disabled older adults, data at Year 
6 for 2,580 participants (1,198 men and 1,382 women) aged 
76–85 were utilized as the baseline in these analyses.
Invecchiare in Chianti.—In 1998–1999, 1,154 men and 
women aged 65 and older were recruited from population-
based registries in two Italian towns (Bagno a Ripoli in 
Tuscany and Greve in Chianti) to study subsystems affect-
ing walking ability (27). The study oversampled for adults 
aged 90+. In 2001–2002, 836 participants (365 men and 
471 women) aged ≥68 years were followed up and had data 
on body composition and/or physical performance were 
used for these analyses.
osteoporotic Fractures in Men Study.—In 2000–2002, 
5,994 men who were aged ≥65 years, able to walk inde-
pendently, and did not report bilateral hip replacements 
were recruited at six U.S. clinical centers (Birmingham, 
Alabama; Minneapolis, Minnesota; Palo Alto, California; 
Monongahela Valley, near Pittsburgh, Pennsylvania; 
Portland, Oregon; and San Diego, California) to evaluate 
the epidemiology of osteoporosis and fractures (28,29). 
In clinic follow-up visits occurred approximately every 
2–3 years. Data on body composition and/or physical per-
formance from the baseline visit were available in 5,993 
men.
Rancho Bernardo Study.—In 1972, 6,728 men and 
women aged 30–79 years were recruited from a southern 
California community (Rancho Bernardo, California) to 
evaluate the risk factors for heart disease (30). Starting in 
1988, participants returned to clinic every 4 years for body 
composition and physical performance assessments. Data 
on body composition and/or physical performance from 
exam cycle 7, 1992–1996, were available in 1,238 partici-
pants (477 men and 761 women).
Study of osteoporotic Fractures.—In 1986–1988, 
9,704 white women aged ≥65  years were recruited at 
four U.S. clinical centers (Baltimore, Maryland; Portland, 
Oregon; Pittsburgh, Pennsylvania; and Minneapolis, 
Minnesota) to evaluate the epidemiology of osteoporosis 
and fractures (31). Recruitment was initially limited to 
white women due to low incidence of fractures in other 
populations. In 1997–1998, 662 African American women 
were additionally recruited (32). Participants returned to 
clinic every 2–3 years for repeat assessments. Data on body 
composition and/or physical performance were available in 
7,008 white women from Visit 6 and 662 African American 
women from Visit 1 for these analyses.
Measures
Physical performance and strength.—Gait speed was 
defined as the length of the walking course divided by the 
time it took subjects to walk the course at their usual pace. 
If more than one walking test was administered, the average 
gait speed (m/s) was used. Except for the Boston Puerto 
Rican Health Study (BPRHS) and Clinical Trials studies, 
the walking courses were 4 or 6 m long and were consid-
ered equivalent. Walking courses that were longer or shorter 
were converted to a speed that would have been achieved 
on a 4- or 6-m course using previously published equations 
(33). Gait speed was not measured in Rancho Bernardo. 
Participants were asked to rise once from a standard chair 
without using their arms. If able to rise once successfully, 
participants were then asked to complete five chair stands 
and the time to complete the chair stands was recorded 
in seconds. Chair stand was not measured in Age, Gene/
Environment Susceptibility-Reykjavik Study. Grip strength 
was measured by a handheld dynamometer, and the   thE FNIh SARCoPENIA PRoJECt  551
maximum value from either hand was analyzed. Most stud-
ies used a Jamar dynamometer (Sammons Preston Rolyan, 
Bolingbrook, IL) (34).
Body composition.—Total body fat mass and total bone-
free lean mass (kg) were acquired from total body scans 
using fan-beamed dual-energy x-ray absorptiometry 
(Hologic, Waltham, MA or Lunar, Madison, WI) using 
standardized protocols (35,36). Appendicular lean mass 
(ALM) was the sum of lean mass from both arms and legs. 
Participants missing lean mass measurements for an arm or 
leg were excluded. The validity and reproducibility of dual-
energy x-ray absorptiometry have been reported previously. 
In Invecchiare in Chianti, body composition was measured 
using peripheral quantitative computed tomography of the 
calf. For Invecchiare in Chianti, estimated ALM was avail-
able only in men and was derived from equations from 
Osteoporotic Fractures in Men Study that included height, 
weight, waist circumference, fat area, muscle area, and 
muscle density. In Age, Gene/Environment Susceptibility-
Reykjavik Study, body composition was measured with 
bioelectrical impedance (Xitron Hydra ECF/ICF Bio-
Impedance Spectrum Analyzer).
Covariates.—Height (cm) was measured on Harpenden 
stadiometers and weight (kg) was measured on standard 
balance beam or digital scales using standard protocols with 
participants wearing light clothing without shoes. Body 
mass index was calculated as weight divided by height2 (kg/
m2). Chronic diseases including diabetes, congestive heart 
failure, chronic obstructive pulmonary disease, and cancer 
were collected where possible. The definition of these dis-
eases was study specific and dichotomized as present or 
absent.
the FNIh Conference.—The three and a half day confer-
ence began with an overview of the issues and perspectives 
of experts from organizations with an interest in aging and 
muscle. Subsequent sessions presented participant charac-
teristics of the studies that contributed data to the pooled 
analyses, the rationale and methodological approaches to 
analyses, preliminary cutpoints for clinically relevant weak-
ness and low lean mass, and their predictive validity. After 
that, breakout groups and panels commented on strengths, 
limitations, and need for further work based on these pre-
liminary findings. On the last day, panels addressed unre-
solved issues related to clinical trial design to test novel 
agents that have the potential to benefit older persons with 
weakness and low lean mass. Also, representatives from 
professional organizations provided feedback and recom-
mendations. Conference attendees were asked to respond to 
a survey regarding level of agreement with key statements 
related to the work of the FNIH Project. The conference 
agenda and key presentations can be found at http://bio-
markersconsortium.org/sarcopenia_pdfs.html.
Statistical Analysis
We present descriptive analyses for categorical and con-
tinuous variables. All descriptions and subsequent analyses 
are presented separately by gender because body composi-
tion and strength differ greatly by gender.
Results
A total of 30,772 participants participated in the nine 
sets of studies. However, 3,633 were <65 years old and 515 
participants with inaccurately measured gait speed were 
excluded, leaving 26,625 participants (11,427 men and 
15,198 women) who were included the pooled data sample.
Baseline characteristics by gender and study are shown 
in Tables 1 and 2. The average age was 75.2 (±6.1 SD) 
and 78.6 (±5.9) years for men and women, respectively. 
Men had a higher prevalence of diabetes and cancer than 
women. The prevalence of obesity was high in both gen-
ders, although men were on average heavier than women. 
Men had greater lean mass (both appendicular and leg) and 
grip strength, walked faster, and completed the five chair 
stands faster. About 5% men and 10% women were unable 
to rise from a chair without the use of their arms. Of the 
participants with gait speed measurements, 10% of men and 
31% of women had gait speed ≤ 0.8 m/s.
Because recruitment criteria were different for each study, 
there were several characteristic differences between stud-
ies. For example, the prevalence of slow walking speed (gait 
speed ≤ 0.8 m/s) varied. In men, the Osteoporotic Fractures 
in Men Study and the Health, Aging, and Body Composition 
study had the lowest percentage of slow walkers, whereas 
BPRHS and FHS Original study had the highest. In women, 
FHS Offspring, Clinical Trials, and the Health, Aging, and 
Body Composition studies had the lowest percentage of 
slow walkers, whereas the BPRHS and FHS Original study 
had the highest percentage. Participants who were slow 
walkers (gait speed ≤ 0.8 m/s) had higher body mass index, 
lower grip strength, and higher prevalence of self-reported 
diabetes, congestive heart failure, and chronic pulmonary 
disease. There was a large difference in mean grip strength 
in men by study (range 27.6–41.6 kg); men in the Clinical 
Trials, FHS Original, and BPRHS had lower grip strengths. 
In women, there was less variability in grip strength (range 
15.8–23.7 kg). Except for higher ALM in African American 
women in Study of Osteoporotic Fractures study (19  kg) 
and lower ALM in Rancho Bernardo Study women (14 kg), 
who had lower body mass index, the differences in mean 
ALM in women between studies were small.
Regarding the research findings from the Conference, 
participants who returned surveys (n = 66) reported the 
strongest level of agreement with a statement regarding the 
use of grip strength to initially assess weakness in a clini-
cal setting (Supplementary Appendix Table 1). Other state-
ments with moderately strong levels of agreement included 
the use of physical performance measures to identify 552  StuDENSkI Et AL.
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persons at risk for disability and the proposed clinical sce-
nario for sequential screening based on mobility perfor-
mance, strength testing, and body composition assessment. 
The respondents reported lower levels of agreement with 
the use of absolute appendicular lean body mass as a cri-
terion for low mass and preferred a measure that accounts 
for body mass. Respondents did not feel that lean mass 
cutpoints without adjustment for body mass were ready for 
clinical use. Respondents also commented on clinical rel-
evance (Supplementary Appendix Table 2). Overall, there 
continues to be concern about how to use the term “sarco-
penia.” On the other hand, there was broad support for the 
existence of a clinically important condition of low mass 
and weakness, that weakness is a clinically relevant state, 
and that mobility impairment by performance and self-
report are clinically relevant outcomes that are likely related 
to low mass and weakness.
Recommendations for further analyses by the FNIH con-
sortium (Supplementary Appendix Table 3) emphasized the 
need to more carefully examine (i) the influence of body 
mass, (ii) the potential influence of gender differences in 
gait speed on grip strength cutpoints, (iii) the relationship 
between lean mass and gait speed, and (iv) to compare the 
cutpoints derived from the FNIH Sarcopenia analyses to 
other proposed criteria available in the literature. Based 
on these recommendations, additional analyses were per-
formed. Detailed findings are presented in the individual 
manuscripts, but the final cutpoints are summarized here 
(Table 3).
Finally, conference respondents made several rec-
ommendations regarding directions for future research 
(Supplementary Appendix Table  4). Among those most 
emphasized were the need to study these relationships in 
populations with a higher prevalence of mobility limitations 
and the need to develop criteria for low muscle quality.
Discussion
The FNIH Sarcopenia Project offers a unique opportu-
nity to carry out a key next step toward a consensus defi-
nition of sarcopenia. In this series, we hope to provide 
detailed evidence about clinically relevant criteria for 
weakness and low muscle mass that are based on statisti-
cally sound methods. The Sarcopenia Project incorporates 
an exceptionally large, diverse, and well-characterized set 
of populations. The pooled sample represents both genders, 
diversity of race and ethnicity, multiple geographic regions, 
and a range of health and functional states. This diversity 
provides important support for the generalizability of our 
findings and permits evaluation of subgroup effects. From 
an analytic perspective, the very large sample size of both 
men and women creates the potential for adequate cell sizes 
for analyses based on a range of categories of strength and 
body composition. Because many participating studies 
included alternate measures of physical function, strength, 
and body composition, we are able to perform a range of 
sensitivity and supplementary analyses to evaluate whether 
findings would differ substantially using other cutpoints or 
measures. We envision that these findings will be used by 
experts as they continue to clarify and refine the terminol-
ogy and develop consensus criteria for a clinical condition 
of sarcopenia.
The rationale and conceptual framework underlying our 
work is based on the growing consensus of experts about the 
clinical and functional consequences of age- and disease-
related changes in muscle. The central functional role of 
muscle is to provide force for body movements and actions, 
so a treatment that addresses muscle dysfunction should 
improve body movements and actions. Mobility is one 
way to assess impairments due to clinical states of function 
that are related to muscle and is an important component 
of functional independence and disability. Mobility can 
be measured reliably using performance measures (33). In 
addition, mobility is a useful and possibly cardinal indica-
tor of function because decreases in mobility often precede 
more advanced forms of disability such as dependence in 
self-care (33). Mobility as a primary indicator of functional 
ability is also more closely linked to muscle function and 
less confounded by factors such as cognitive impairment 
than is a global indicator like dependence in self-care.
We believe that criteria for reduced lean mass should be 
reevaluated because those in current use have significant 
limitations. The original definition of sarcopenia based 
on reduced muscle mass alone was designed to parallel 
the definition of reduced bone mass, in that “abnormal” is 
defined in relation to the distribution of bone mass in the 
population. The definition proposed for sarcopenia was a 
ratio of muscle mass to height 2 SDs below the mean found 
in healthy young persons drawn from the Rosetta Stone 
project (37). Whereas low bone mass has consistently been 
associated with risk of future fracture, low muscle mass 
alone is not consistently associated with adverse outcomes, 
but rather appears to become a problem only when it is 
associated with weakness. Therefore, we believe that cri-
teria for low muscle mass should be determined based on 
the risk of weakness. Thus, we believe that our overarching 
Table 3.  Recommendations for Cutpoints for Weakness and Low 
Lean Mass in Men and Women
Cutpoint Men Women
Weakness
Recommended: grip strength 
(GSMAX)
<26 kg <16 kg
Alternate: grip strength adjusted 
for BMI (GSMAXBMI)
<1.0 <0.56
Appendicular lean body mass
Recommended: ALM adjusted 
for BMI (ALMBMI)
<0.789 <0.512
Alternate: ALM <19.75 kg <15.02 kg
Notes: ALM = appendicular lean mass; BMI = body mass index.  thE FNIh SARCoPENIA PRoJECt  555
approach is well justified in that it is based on using mobil-
ity impairment as the clinically relevant functional state to 
determine meaningful weakness and then linking lean mass 
to the relationship with weakness.
We believe that our operational choices of physical per-
formance cutpoints for analysis are reasonable. First, we 
provide evidence that our primary indicator, a usual gait 
speed of less than 0.8 m/s, is associated with reduced sur-
vival, increased disability, and is recommended by experts 
(15). Second, we evaluate alternate cutpoints and indica-
tors of mobility disability. Third, we note that many widely 
accepted markers of a condition or disease, for example, 
blood pressure to diagnose hypertension, blood sugar to 
diagnose diabetes, or cholesterol level to diagnose hyper-
lipidemia, are all actually arbitrary cutpoints representing 
expert opinion of what is actually a continuous, graded rela-
tionship with serious adverse events. In fact, for all three of 
the examples (blood pressure, blood sugar, and cholesterol 
level), the cutoff values have evolved over time (38–40). 
Thus, we feel that we have attempted to select a justifia-
ble initial cutpoint and recognize that future research may 
evolve toward a higher or lower value.
Although longitudinal analyses are superior to cross-
sectional analyses for questions related to causation and 
prognosis, we note that cross-sectional analyses as used 
here for our work on grip strength and lean mass cutpoints 
(9,10) are most appropriate for establishing clinical diag-
nostic cutpoints based on concurrent clinical presentation 
and laboratory findings. We emphasize that we are not look-
ing for cross-sectional associations, but rather for optimal 
diagnostic cutpoints using approaches such as classification 
and regression tree analysis and diagnostic test characteris-
tics such as sensitivity and specificity.
Conference attendees generally supported the appropri-
ateness of measures of grip strength and physical perfor-
mance. Based on the feedback from conference participants, 
we refined and extended our analyses. With our existing 
resources, we were able to address all but one of the rec-
ommended additional analyses (Supplementary Appendix 
Table 2). Specifically, because of concerns regarding the influ-
ence of body mass on the relationships among performance, 
strength, and lean mass, we performed multiple additional 
analyses to clarify the need to adjust or stratify lean mass esti-
mates for body mass (9–11). In addition, as recommended by 
the conference participants, we examined alternative cutpoints 
for gait speed and performed a series of analyses comparing 
our findings to other recommended criteria (12).
The findings reported in this series represent our best cur-
rent estimates for cutpoints for clinically relevant weakness 
and low lean mass. We note that our final recommendation is 
to use unadjusted grip strength and body mass–adjusted ALM. 
Overall, we found that, in men, body mass adjustment had 
little effect on the relationships between walking speed and 
strength, or between strength and lean mass, but had notice-
able effects in women (see (9,10) for details). These effects 
in women were present for both strength and mass but had 
only modest impact on model fit for grip strength (9), whereas 
the effects were larger for lean mass (10). In addition, we felt 
that unadjusted grip strength might be simpler to use clinically 
and, because it seemed less reasonable to adjust both strength 
and lean mass, we recommend body mass adjustment for lean 
mass but not strength. Also, the combination of unadjusted 
grip strength and body mass–adjusted lean mass had the least 
heterogeneity of future associations with incident mobility 
limitations across different study samples in women (11).
This work has numerous strengths, including sample 
sizes that are by far the largest to ever be applied to this 
topic, broad representation of community-dwelling older 
persons, an explicit conceptual framework, extensive use of 
sensitivity, and cross-validation analyses and supplemental 
analyses based on recommendations from multiple experts. 
We envision that these criteria might be used to plan pre-
vention studies in which older persons with weakness and 
low lean mass receive interventions designed to reduce the 
incidence or increase the time to onset of mobility impair-
ment. Alternatively, these criteria might be used to identify 
candidates for treatment studies of persons who already 
have mobility impairment, weakness, and low lean mass.
We faced numerous challenges in our efforts to pursue 
this work. It became obvious early on that mobility impair-
ment is not common among older adults who participate in 
research studies and that persons with baseline weakness 
and mobility impairment are more likely to have missing 
data and a higher risk of loss to follow-up. It is possible that 
relationships among function, weakness, and mass are dif-
ferent and perhaps more robust among more vulnerable or 
frail individuals. Also, our participating studies for the most 
part provide longitudinal follow-up at intervals of years. 
Although this interval is entirely appropriate for examining 
some outcomes important to aging, the time interval may 
be too long to examine effects of acute changes in health, 
nutrition, and activity on body composition. Data harmo-
nization was also a challenge. For example, studies used 
more than one brand and more than one generation of dual-
energy x-ray absorptiometry machines to measure body 
composition, more than one type of hand-grip dynamom-
eter, and more than one distance for calculating gait speed. 
For each of these harmonization issues, we performed sets 
of analyses, described in the subsequent manuscripts, to try 
to evaluate the impact of these variations.
Other challenges of this work included weighing 
the advantages and disadvantages of several different 
approaches to criteria that emerged from our analyses. For 
example, we found two sets of grip strength cutoffs and 
chose to use the more stringent cutoff in order to limit 
false positives and to pursue our overall strategy of a con-
servative set of criteria. We also found challenges when 
dealing with differences in optimal types of criteria for 
men and women. Although simple indicators of lean mass 
appear to work well in men, obesity appeared to have a 556  StuDENSkI Et AL.
strong modifying effect on the impact of lean mass on gait 
slowness in women. For consistency, we chose to propose 
the same types of indicators (eg, ALMBMI) in both men and 
women. However, it is possible that the effects of body 
composition on function are truly different by gender. If 
further research supports a gender difference, it is possi-
ble that future criteria may incorporate different types of 
indicators for men than women. Because there may be dif-
ferences in the relationship between lean mass, strength, 
and function within important subgroups, we had hoped 
to perform subanalyses stratified by race and ethnicity. 
However despite our efforts to involve multiple stud-
ies with diverse populations, we did not have sufficient 
sample sizes among populations of African Americans 
or Hispanics to perform these planned analyses. Many 
unanswered questions remain but there are many excit-
ing directions for future work (Supplementary Appendix 
Table 4). With involvement of the participating studies, 
the comprehensive data set that we created could poten-
tially be used to address some of these questions, whereas 
others would require the use of additional existing data 
sets or even new research planning. Important gaps in 
knowledge that could be pursued in the next few years 
include evaluating the impact of weakness and low lean 
mass on the incidence of other important outcomes such 
as hospitalization, self-reported disability, and quality of 
life. It would also be useful to assess the incidence of new 
weakness and low lean mass over time and evaluate fac-
tors that contribute to it. Although we chose to base our 
weakness indicator on the more severe degree of “very 
low” grip strength (9), it might be informative to evaluate 
the clinical implications of the less stringent indicator of 
weakness with and without low lean mass. In the longer 
term, clinical trials of interventions based on pharmaco-
logic agents, exercise, and nutrition, separately and even 
together, can help determine issues related to the respon-
siveness of individuals with various degrees of weakness 
and low lean mass. Such trials can also assist in building 
knowledge about criteria for clinically meaningful change 
in relevant outcomes. Using the findings here as well as 
other developments in the field, professional organizations 
and expert panels might make refined recommendations 
regarding terminology, criteria, and help prioritize further 
work. We hope that our efforts will provide a resource to 
the field as we attempt to identify, prevent, and treat this 
important contributor to disability in late life.
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